AU2023207801B2 - Tryptamine compositions and methods - Google Patents

Tryptamine compositions and methods

Info

Publication number
AU2023207801B2
AU2023207801B2 AU2023207801A AU2023207801A AU2023207801B2 AU 2023207801 B2 AU2023207801 B2 AU 2023207801B2 AU 2023207801 A AU2023207801 A AU 2023207801A AU 2023207801 A AU2023207801 A AU 2023207801A AU 2023207801 B2 AU2023207801 B2 AU 2023207801B2
Authority
AU
Australia
Prior art keywords
disorder
salt
pharmaceutically acceptable
acceptable salt
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2023207801A
Other languages
English (en)
Other versions
AU2023207801A1 (en
Inventor
Kenneth L. Avery
James He HUANG
Alex Nivorozhkin
Pradip M. Pathare
Mohammed I. SHUKOOR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybin IRL Ltd
Original Assignee
Cybin IRL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybin IRL Ltd filed Critical Cybin IRL Ltd
Publication of AU2023207801A1 publication Critical patent/AU2023207801A1/en
Application granted granted Critical
Publication of AU2023207801B2 publication Critical patent/AU2023207801B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2023207801A 2022-01-14 2023-01-13 Tryptamine compositions and methods Active AU2023207801B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263299599P 2022-01-14 2022-01-14
US63/299,599 2022-01-14
US202263384704P 2022-11-22 2022-11-22
US63/384,704 2022-11-22
PCT/EP2023/050702 WO2023135237A1 (en) 2022-01-14 2023-01-13 Tryptamine compositions and methods

Publications (2)

Publication Number Publication Date
AU2023207801A1 AU2023207801A1 (en) 2024-06-27
AU2023207801B2 true AU2023207801B2 (en) 2026-01-22

Family

ID=85018123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023207801A Active AU2023207801B2 (en) 2022-01-14 2023-01-13 Tryptamine compositions and methods

Country Status (9)

Country Link
US (1) US20250051279A1 (https=)
EP (1) EP4463440A1 (https=)
JP (1) JP2025502208A (https=)
KR (1) KR20240134951A (https=)
AU (1) AU2023207801B2 (https=)
CA (1) CA3259235A1 (https=)
IL (1) IL313889A (https=)
MX (1) MX2024008691A (https=)
WO (1) WO2023135237A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4618981A1 (en) 2022-11-17 2025-09-24 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ID28302A (id) 1999-01-14 2001-05-10 Teijin Ltd Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
JP4795637B2 (ja) 2001-09-28 2011-10-19 カーブ テクノロジー，インコーポレイティド 鼻ネブライザー
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
KR20240096817A (ko) * 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US12042564B2 (en) * 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний
JP2023544724A (ja) * 2020-10-02 2023-10-25 サイビン アイアールエル リミテッド 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム
IL303288A (en) * 2020-12-01 2023-07-01 Small Pharma Ltd N,N-Dimethyltryptamine compounds partially or fully deuterated

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEATON J M ET AL: "A comparison of the behavioral effects of proteo- and deutero-N, N-dimethyltryptamine", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 16, no. 5, 1982, pages 811 - 814 *
MORRIS PHILIP E JR ET AL: "Indolealkylamine metabolism: Synthesis of deuterated indoleakylamines as metabolic probes", J. LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 33, no. 6, 1993, pages 455 - 465 *

Also Published As

Publication number Publication date
CA3259235A1 (en) 2023-07-20
WO2023135237A1 (en) 2023-07-20
KR20240134951A (ko) 2024-09-10
JP2025502208A (ja) 2025-01-24
EP4463440A1 (en) 2024-11-20
MX2024008691A (es) 2024-07-19
IL313889A (en) 2024-08-01
US20250051279A1 (en) 2025-02-13
AU2023207801A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
AU2022342266B2 (en) Combination drug therapies
US20250213527A1 (en) Formulations of psilocybin analogs and methods of use
EP4499087A1 (en) Combination of nitrous oxide and 5-ht2a receptor agonists
WO2023156453A1 (en) Phenethylamine derivatives, compositions, and methods of use
US20250236589A1 (en) Therapeutic phenethylamine compositions and methods of use
AU2023207801B2 (en) Tryptamine compositions and methods
AU2023366306A1 (en) Phenethylamine compounds, compositions, and methods of use
JP2025531630A (ja) トリプタミン化合物、組成物、及び使用方法
CN118632835A (zh) 色胺组合物和方法
JP2026513655A (ja) フェネチルアミン化合物、組成物、及び使用方法
CN118234708A (zh) 裸头草碱类似物的调配物和使用方法